Pharming Group Reports Strong Q3 2025 Revenue Growth, Strategic Refocus and Pipeline Advances in Rare Disease Segment
Thursday, November 06, 2025
On November 6, 2025, Pharming Group N.V. (Euronext Amsterdam: PHARM/NASDAQ: PHAR), a Dutch-headquartered rare disease specialist, delivered its preliminary unaudited financial report for the third quarter of 2025, highlighting a notable upturn in revenue, profitability, and cash flow. For pharmaceutical and biotech executives, manufacturers, and commercial strategists in Europe, Pharming’s latest report signals a reaffirmation of its growth and a recalibration of its commercial and R&D strategies to strengthen its niche in rare and ultra-rare diseases.
Pharming's CEO, Fabrice Chouraqui, credited strong operational execution for the company’s quarterly performance. RUCONEST®, its primary recombinant C1 esterase inhibitor indicated for acute Hereditary Angioedema (HAE) attacks, posted a robust US$82.2 million in Q3 revenue—representing a 29% year-over-year gain. Notably, the U.S. remained the cornerstone market, with rising new patient enrollments and an expanding prescriber base, even as new oral competitors entered the on-demand HAE segment in July. For the first nine months of 2025, RUCONEST® revenue rose to US$231.2 million, up 34% from the prior year. These figures underscore Pharming’s operational scaling and market resilience in the competitive U.S. rare disease landscape.
However, in a strategic redirection, Pharming is withdrawing RUCONEST® from registration and/or commercialization in all non-U.S. markets, including Europe, citing chronic lack of financial sustainability. Non-U.S. sales accounted for just 1.3% of product revenue in the quarter (US$1.1 million). Executive leadership emphasized that resources would be redirected to accelerate pipeline opportunities with higher commercial value and sustainable long-term growth prospects. The company pledged to ensure continuity of care for existing patients impacted by this pivot, reflecting an industry trend toward portfolio focus and operational optimization amid shifting market access and reimbursement climates.
Leniolisib (Joenja®), an oral PI3K delta inhibitor approved for activated phosphoinositide 3-kinase delta syndrome (APDS), also recorded significant momentum. Third-quarter Joenja® revenue reached US$15.1 million—a 35% rise from Q3 2024. Crucially, the therapy saw a major uplift in commercial uptake both in the U.S. and in the U.K. following its April 2025 launch, with a 25% increase in U.S. patients on paid therapy and growing funded access programs in Europe. Executives highlighted the acceleration in EU and Rest-of-World sales, driven mainly by strong patient uptake and structured market access in the U.K. Market expansion for leniolisib is advancing, with the FDA having granted priority review for a pediatric label extension for children aged 4-11 (PDUFA target: January 31, 2026) and pending clinical data in children 1-6, pointing to new revenue streams and elevated market penetration in Europe pending good evaluation outcomes and reimbursement.
In terms of pipeline development, Pharming is pushing forward with multiple clinical programs. The company reported progress in two ongoing Phase II trials for leniolisib in primary immunodeficiency disorders (PIDs) with immune dysregulation, as well as the pivotal FALCON study for KL1333 in mitochondrial DNA-driven primary mitochondrial disease—an area of significant unmet medical need in Europe. These advances reinforce Pharming’s R&D commitment and its relevance to biopharma partners, rare disease consortia, and clinical trial networks in the region.
On the organizational front, Pharming announced several executive changes to align leadership with its strategic ambitions. Kenneth Lynard joined as Chief Financial Officer in October 2025, bringing two decades of global finance experience in the life sciences sector. Additionally, Leverne Marsh was appointed Chief Commercial Officer, effective January 1, 2026, in succession of Stephen Toor. These appointments are intended to strengthen Pharming’s global commercial infrastructure as it navigates competitive launches and deepens its footprint in the rare disease sector.
Pharming’s third-quarter update provides actionable insights for European pharma executives: a renewed prioritization of high-value rare disease assets, a focus on capital efficiency, strong operating cash flows (US$32 million in Q3), and agility in clinical and commercial strategy. The withdrawal of RUCONEST® from non-U.S. markets also raises broader questions for peers regarding product lifecycle management, ROI in fragmented European markets, and the value of commercial diversification versus specialization. Pharming’s evolving model, centered on scale in select rare indications and rapid regulatory-driven expansion, is likely to shape strategic playbooks for European biopharma and CDMO partners in 2026 and beyond.
